For investors
For investors
Pharmena SA is a publicly listed life science company focused on developing innovative solutions based on the biological potential of the 1-MNA molecule.
The Company is listed on the main market of the Warsaw Stock Exchange and is committed to transparent communication with shareholders and the capital market.
Overview of Pharmena’s activities, development areas and core technologies.
Pharmena SA is a life science company listed on the main market of the Warsaw Stock Exchange. The Company focuses on the development and commercialization of innovative products and technologies based on the biological potential of the 1-methylnicotinamide (1-MNA) molecule.
Pharmena’s business model is based on translating scientific discoveries into practical product and technology solutions across different application areas. The Company’s activities include scientific research, product development and commercialization.
Pharmena develops its activities across three complementary areas reflecting different stages of innovation and market application.
LongevityThis area focuses on the development and commercialization of products supporting healthy aging and long-term vitality. The Endotelio platform is dedicated to science-based solutions built on the biological properties of the 1-MNA molecule.
Topical technologiesThis area includes research and development activities focused on products intended for local application in selected medical and specialized fields. These activities are conducted within the Synerixa platform.
BioscienceThe Bioscience area focuses on advancing scientific understanding of the biology, health potential, and therapeutic applications of the 1-MNA molecule. These activities are carried out within the MNAxis platform.
Through this development model, Pharmena combines near-term product commercialization with mid- and long-term research and development programs.
Business activity
Overview of Pharmena’s activities, development areas and core technologies.
Pharmena SA is a life science company listed on the main market of the Warsaw Stock Exchange. The Company focuses on the development and commercialization of innovative products and technologies based on the biological potential of the 1-methylnicotinamide (1-MNA) molecule.
Pharmena’s business model is based on translating scientific discoveries into practical product and technology solutions across different application areas. The Company’s activities include scientific research, product development and commercialization.
Pharmena develops its activities across three complementary areas reflecting different stages of innovation and market application.
Longevity
This area focuses on the development and commercialization of products supporting healthy aging and long-term vitality. The Endotelio platform is dedicated to science-based solutions built on the biological properties of the 1-MNA molecule.
Topical technologies
This area includes research and development activities focused on products intended for local application in selected medical and specialized fields. These activities are conducted within the Synerixa platform.
Bioscience
The Bioscience area focuses on advancing scientific understanding of the biology, health potential, and therapeutic applications of the 1-MNA molecule. These activities are carried out within the MNAxis platform.
Through this development model, Pharmena combines near-term product commercialization with mid- and long-term research and development programs.
Pharmena develops and commercializes solutions based on the biological potential of the 1-methylnicotinamide (1-MNA) molecule, combining research and development activities with the creation of commercial value from its technologies and intellectual property.
The Company’s strategy is built around three complementary pillars: longevity (Endotelio), topical technologies (Synerixa), and bioscience (Mnaxis). This structure enables Pharmena to pursue projects with different development horizons simultaneously, from product commercialization to long-term research and development programs.
Pharmena’s objective is to develop innovative products and technologies, expand scientific knowledge related to 1-MNA, and maximize the value of its scientific, technological, and intellectual property assets.
Pharmena’s objective is to develop innovative products and technologies, expand scientific knowledge related to 1-MNA, and maximize the value of its scientific, technological, and intellectual property assets.
Company strategy
Pharmena develops and commercializes solutions based on the biological potential of the 1-methylnicotinamide (1-MNA) molecule, combining research and development activities with the creation of commercial value from its technologies and intellectual property.
The Company’s strategy is built around three complementary pillars: longevity (Endotelio), topical technologies (Synerixa), and bioscience (Mnaxis). This structure enables Pharmena to pursue projects with different development horizons simultaneously, from product commercialization to long-term research and development programs.
Pharmena’s objective is to develop innovative products and technologies, expand scientific knowledge related to 1-MNA, and maximize the value of its scientific, technological, and intellectual property assets.
Pharmena’s objective is to develop innovative products and technologies, expand scientific knowledge related to 1-MNA, and maximize the value of its scientific, technological, and intellectual property assets.
Authorised advisor
4DF Spółka z ograniczoną odpowiedzialnością
i Wspólnicy Spółka Komandytowa
Registered office:
ul. Sienkiewicza 9, 90-113 Łódź
Contact person:
Jakub Chabin
tel. 042 632 80 29
fax. 042 632 80 01
e-mail: office@4df.eu
www.4df.eu
Investor relations
The person responsible for investor relations:
Tomasz Gutowski | InnerValue Investor Relations
phone: +48 794 444 574
e-mail: t.gutowski@innervalue.pl
Wilcza 46 | Floor 1
00-679 Warsaw
Poland
Contact
Authorised advisor
4DF Spółka z ograniczoną odpowiedzialnością
i Wspólnicy Spółka Komandytowa
Registered office:
ul. Sienkiewicza 9, 90-113 Łódź
Contact person:
Jakub Chabin
tel. 042 632 80 29
fax. 042 632 80 01
e-mail: office@4df.eu
www.4df.eu
Investor relations
The person responsible for investor relations:
Tomasz Gutowski | InnerValue Investor Relations
phone: +48 794 444 574
e-mail: t.gutowski@innervalue.pl
Wilcza 46 | Floor 1
00-679 Warsaw
Poland
Advancing Science.
Creating Value.
contact
PHARMENA S.A.
ul. Gdanska 47/49
90-729 Łodz, Poland
phone: +48 42 280 77 07
office@pharmena.eu
links
Advancing Science.
Creating Value.
contact
PHARMENA S.A.
ul. Gdanska 47/49
90-729 Łodz, Poland
phone: +48 42 280 77 07
office@pharmena.eu